

Index

- abciximab, 285, 289
 absolute refractory period
 (ARP), 45–46, 69–70
 acarbose, 276
 accelerometers, 318
 acclimatisation, 30
 ACE inhibitors, 166, 249, 251,
 255
 acetazolamide, 31, 252–253
 acetylcholine, 82–85, 87–88,
 213–214, 217,
 221–223, 266–267,
 270, 316
 breakdown, 85, 222
 receptors, 82–84, 213–215,
 221, 223–224, 318
 acetylcholinesterase, 83, 85,
 166, 172, 213, 222–224
 acetylcholine synthesis, 214
 acetylcholinesterase inhibitors,
 222–223
 acetylcoenzyme, 85
 acetylcoenzyme a, 85
 acid–base dissociation
 constant, 150
 acidosis, 23–24, 26, 28–29, 58,
 101–102, 215, 217, 220
 acquired immunity, 138–142
 action potential, 46, 69, 70, 76,
 87–88, 170, 221,
 254–255, 259
 acetylcholine release, 222
 calcium ion influx, 213
 cardiac muscle, 45–46, 257
 local anaesthetics, 227
 motor neurones, 75
 Nernst equation, 68
 nerve stimulation, 69
 pacemaker cells, 42–44,
 46–47, 254–255
 sodium channels and, 241,
 242
 activated charcoal, 166, 171,
 247
 active zones, 83–84
 acute renal failure, 220, 238
 acute respiratory distress
 syndrome (ARDS), 6,
 19
 acute spinal cord injury, 73
 adenosine, 131, 255–256
 adenosine triphosphate
 (ATP), 15, 51–52, 69,
 88–89, 109–111, 137,
 260, 266
 adenylate cyclase, 260
 adenylyl cyclase, 79–80,
 168–169
 adrenal glands, 79, 115,
 120–121, 124, 261
 adrenaline, 79, 81, 125, 154,
 228–230, 231, 255,
 259–262
 adrenaline infusions, 262
 adrenal medulla, 79, 111, 120,
 124–125, 260, 261
 adrenergic receptors, 78,
 79–80, 259–260
 adrenocorticotrophic hormone,
 114, 115, 123
 adrenoreceptors, 80, 260–261
 agents, antiplatelet, 285, 300,
 302
 alcohol dehydrogenase, 154
 aldasorber, 352
 aldosterone, 94, 112, 115, 121,
 124
 aldosterone secretion, 124
 alfentanil, 189, 194, 236
 alteplase, 135, 289
 alveolar concentration, 199,
 206, 210, 211
 alveolar gas equation, 15–18, 21
 alveolar pressure, 5–6, 12
 alveolar ventilation, 3, 14,
 15–17, 199, 381
 alveoli, 7–8, 10, 11–13, 18, 23,
 199–200, 211
 fluid accumulation, 23
 gas equation, 15, 17
 pressure inside, 7–8, 11–12,
 32
 surface tension, 7
 surfactants, 8
 Alzheimer's disease, 66
 amides, 226, 228–230
 amino acids, 67, 109, 112, 115,
 126, 129, 132, 135–137
 aminoglycosides, 214, 216,
 281, 283
 amiodarone, 118, 151, 170,
 173, 232, 254–255,
 256, 257–259
 amplifiers, 308–309, 310
 amyloid plaques, 66
 amylopectin, 96
 anaesthesia, 161–163,
 193–194, 199–201,
 206–208, 210–211,
 314–315, 329–330,
 341–342
 epidural, 129, 190, 230
 general, 145, 148, 192, 195,
 206, 208, 210, 272
 hypotensive, 249, 251
 induction, 145, 187, 190,
 192–193, 194, 201, 208,
 210
 inhalational, 65, 197–207,
 210, 348, 367
 local, 65, 148, 151, 153,
 216–217, 226–232,
 260, 261
 neuraxial, 145–146, 373
 neuromuscular blockade,
 195, 214, 216–218, 220,
 222, 224–225, 311,
 315–318
 spinal, 145, 148, 230,
 289–290
 TIVA, 205, 208
 anaesthetic gases, 211, 319,
 337, 349–350, 353
 analgesia, 162, 191, 212,
 230–231, 234–235, 251
 anaphylaxis, 195, 219, 258,
 260, 261–262, 271,
 282, 288
 anatomical dead-space, 12–15
 angiotensins, 93, 124, 128, 166
 anion gap, 101
 ANOVA, 298–299
 antacids, 166, 258, 264, 267
 antagonists
 benzodiazepine, 247
 calcium channel, 216–217,
 249, 256

- antagonists (cont.)
 irreversible, 175
 muscarinic, 171
 non-competitive, 175, 177, 190
 opioid, 271
 reversible, 175
 anterior pituitary, 67, 112–115, 117, 123–124, 128, 145
 antiarrhythmic drugs, 170, 232, 242, 253–256, 259
 anti-bacterial drugs, 280–281, 283–284
 antibiotic colitis, 283
 antibiotics, 66, 216, 280, 282, 283, 399
 antibodies, 140–141
 anticoagulants, 172, 239, 285, 290, 300, 301
 anti-convulsants, 169, 188, 241–245
 antiemetics, 146, 184, 198, 244, 268, 270–273
 anti-fungal agents, 284
 antihypertensive drugs, 170, 249, 251, 253
 antimuscarinic agents, 224, 272
 anti-parasitic agents, 280
 antiplatelet agent, 302
 anti-static precautions, 415–416
 aortic pressure, 21, 34–35
 apical membrane, 264–266
 arachidonic acid, 139, 238–239
 arginine, 66, 136–137
 arterial blood, 18, 25, 27, 73, 199–200, 360–361, 370, 391
 arterial oxygen saturations, 360–362
 arterial partial pressure of oxygen, 18, 362
 arterial–venous concentration difference, 402
 arterial–venous pressure difference, 12
 aspirin, 172, 238, 285, 289
 astrocytes, 59, 65–66
 atenolol, 250
 atracurium, 154, 180–181, 215–216, 244
 atrial contraction, 33, 35, 37
 atrial fibrillation, 118, 257, 262, 288, 301, 362, 390
 atrial natriuretic peptide (ANP), 94–95
 atrio-ventricular node, 39, 42–44, 261
 atrio-ventricular valves, 33–37
 atropine, 181, 224, 255–256, 270–271, 273
 automaticity, 42, 255, 257, 261
 autonomic nervous system, 41, 47, 55, 75, 78, 82, 126
 autoregulation, 40–41, 58–60, 62, 102, 130, 189, 399
 Avogadro's constant, 322
 Avogadro's hypothesis, 305, 322
 bacteria, 142, 280–282
 baroreceptor reflex, 48
 baroreceptors, 47–49, 77, 94, 107
 basal metabolic rate, 50–51, 108, 127, 262
 base excess, 101–102
 basement membrane, 65, 104
 basolateral membrane, 93, 264–267
 basophils, 139
 β -blockers, 171, 249–251
 Benedict–Roth spirometer, 328–329
 benzodiazepine poisoning, 247
 benzodiazepines, 58, 167, 173, 191, 194, 241–242, 244–248
 overdoses, 247
 benzylquinolinium, 244
 Bernoulli effect, 325–326
 Bernoulli principle, 325
 biguanides, 276
 bile, 92, 130, 132, 154, 156, 215
 biliary excretion, 154
 bioavailability, 149–152, 155, 186, 247, 271
 bioelectrical impedance analysis, 93
 bi-phospholipid cell membrane, 92
 birth, 26, 71, 147
 Bispectral Index, 208, 210, 308, 311
 β -lactam antibiotics, 281–282
 β -hydroxybutyric acid, 111
 bladder epithelium, 94
 blood–brain barrier, 4, 62, 64–67, 153, 186–187, 236, 270, 271
 blood flow, 9, 11–12, 40–42, 53, 59–60, 102, 147–148, 426–427
 coronary, 41–42, 53, 257
 pulmonary, 9, 22, 402
 blood:gas partition coefficient, 9, 197–199, 201, 204, 210
 blood pressure, 47–50, 53, 188, 250, 291, 389–392, 393
 blood pressure
 venous, 12, 33, 63, 310, 386
 blood pressure, arterial, 12, 48, 94, 386, 392, 394, 399
 blood samples, 101, 358, 364–365, 402
 body temperature, 30, 113, 371–372
 Bohr effect, 28
 Bowman's capsule, 103–104
 Boyle's law, 319–320, 333
 bradykinin, 67, 139, 166
 breathing systems, 337, 338–340, 347–348, 349, 350–351, 367, 368
 closed, 338
 open, 337
 semi-open, 337
 breathing systems, semi-closed, 337–338, 341–342
 bromocriptine, 272
 brown fat, 80, 372
 Brown–Sequard syndrome, 74
 buffer systems, 99–100
 buffers, 98–100, 396
 bupivacaine, 181, 226–231, 232, 260
 calcium, 84, 88, 90, 119–120, 133, 216–217, 260, 263
 calmodulin, 90
 capacitance, 380, 409–410, 417–418, 425, 426
 capacitors, 304, 409–411, 417–419, 424
 capacity, 1–2, 13, 60, 73, 333, 338, 410, 417–418
 capillaries, 8, 26, 64–65, 86, 91, 104
 capillary blood glucose (CBG), 278–279
 capillary endothelium, 65
 capnography, 314, 347, 363, 367, 369, 370
 main-stream, 368
 side-stream, 368

	Index	431
carbamazepine, 172, 244	central nervous system, 62, 74–75, 192, 216–217, 239–241	compliance, 2, 5, 6–7, 8, 10, 151, 393
carbapenems, 281–282	astrocytes, 65	chest wall, 5–6
carbon dioxide	CSF analysis, 64	factors influencing, 6–7
alveolar, 14–15	drug administration to, 67	lung, 5–7
end-tidal, 220, 366–367	multiple sclerosis, 66	respiratory, 5
carbon dioxide dissociation	vasomotor centres, 47	compound A, 201, 202, 348–349
curve, 19	cephalosporins, 281, 282	concentration effect, 200, 210–211
carbon monoxide, 29, 202, 348–349	cerebral blood flow (CBF), 53, 57–61, 189, 191, 202, 204, 396, 398	conductors, 304, 372, 407–408, 410–411, 422
poisoning, 29, 362	cerebral metabolic rate, 57, 59–60, 184, 188, 189, 191, 202, 397–398	contractility, 38, 172, 202, 391, 401
carbonic anhydrase, 99–100, 265, 366	cerebrospinal fluid (CSF), 4, 57, 62–64, 71, 231, 395, 396–399	contraction, 37, 41, 43, 75–76, 86–88, 90, 257
carboxyhaemoglobin, 28–29, 362	Charles' law, 320–321	core body temperature, 372, 378
cardiac arrest, 42, 81, 219, 231, 232, 260, 261, 370	chemoreceptors, 3–4, 48, 63, 77, 236, 269–270, 272	Cori cycle, 109
cardiac arrhythmias, 219, 258, 271	central, 4, 19, 63	coronary arteries, 38–42
cardiac cycle, 33–34, 41, 395	peripheral, 4	cortisol, 112, 115, 121, 122–124, 128, 192
cardiac failure, 50, 189, 221, 250, 252–253	children, 50, 119, 182, 190, 217, 239, 291, 340	COVID-19, 290
cardiac ischaemia, 194, 250, 262	chiral centre, 180–181	creatine, 137
cardiac muscle, 37, 45, 86, 111, 254, 259, 327, 422	chlorpromazine, 271	cricoid force, 145, 193, 195–196
cardiac output, 20, 23–25, 48–49, 52–54, 143–144, 200, 400–405, 426–427	choline, 66, 85, 213–214, 215, 218, 222	cricoid pressure, 195
estimation, 400–401, 405, 427	chromatography, 355	critical temperature, 209, 321, 333, 336
shunt proportion, 20	chronic mountain sickness, 31	crystalloids, 94, 300
cardiac shunts, 22	cimetidine, 151, 172, 267, 287	current density, 413–415, 422–423
catecholamines, 80–81, 112, 117, 125, 128, 175, 198, 204	circulation, pulmonary, 20, 21–22, 146	Cushing's, 122, 273
cell membranes, 69, 70, 112, 152, 167, 169, 227, 398, 415	cis-atracurium, 216	cyclizine, 244, 270–272
acetylcholine receptors, 84	Clark electrode, 357–358	cyclo-oxygenases, 238, 285
depolarisation, 84, 213	clarythromycin, 283	cytochrome P450 system, 132, 154, 172, 186, 202
fungal, 284	clindamicin, 283	cytokines, 128–129, 139
G-proteins, 168	clopidogrel, 285, 289	
ion diffusion across, 44–45, 68, 167, 221	closing capacity, 2, 13	Dalton (unit), 95
ionised drugs, 152	clotting, 129, 132, 134–135, 366	Dalton's law, 321
membrane potential, 68, 69	clotting cascade, 133	damping, 393–395
potassium permeability, 68	clotting factors, 133, 137, 144	dantrolene, 220, 272
protein binding and, 228	clotting, testing, 134–135	data
receptors, 166	coagulation, 133, 285–286, 421, 422, 423–424	discrete, 291
water impermeable, 93	Coanda effect, 326–327	grouped, 298–299
water transport, 92	codeine, 182	qualitative, 291, 297
cellular immunity, 138, 140	co-induction, 194	deamination, 137
central chemoreceptors, 4, 19, 63	colloids, 94, 95	defibrillators, 406, 409–410, 417–419
	compartment model, 156, 190	biphasic, 419
	competitive antagonism, 223	monophasic, 419
	complement, 138, 142, 259	denervation hypersensitivity, 84
	complement system, 140–142	depolarising neuromuscular blockade, 195, 214, 318

- desflurane, 32, 199, 201–203, 205, 207, 344–346, 348, 349
- dexamethasone, 23, 31, 272, 279
- dextran, 96
- diabetes, 111, 253, 273–275, 277–278
 complications, 274
 perioperative care principles, 264–279
- diaphragmatic paralysis, 73
- diastole, 33–37, 41–42
- diastolic perfusion, 41
- diathermy, 279, 406, 412, 416, 420, 422–424
- differential amplifiers, 308, 411, 425
- Difficult Airway Society, 195
- diffusion hypoxia, 211
- digoxin, 255–260, 262
 toxicity, 258
- dihydroxyphenylalanine, 125
- diltiazem, 251, 254–255
- direct oral anticoagulants (DOAC), 285, 288–290, 301–302
- diuretics, 249, 252–253, 287
 osmotic, 252–253, 398
 potassium-sparing, 249
 thiazide, 249–253
- dobutamine, 23, 81, 260
- domperidone, 270–271, 273
- dopamine, 65, 81, 114–115, 125, 154, 170, 252, 260
- dopamine receptors, 81
- dopexamine, 81, 260
- Doppler effect, 61, 400, 426
- dose-response curve, 176
- droperidol, 244, 271
- drug accumulation, 187
- drug concentrations, 162, 163–164, 176
- drug excretion, 154, 189
- drug interactions, 171, 172, 182, 194, 242, 287
 pharmaceutical
 incompatibility, 171
 pharmacokinetic
 interactions, 171
- duodenum, 132, 267
- earth leakage circuit breakers, 412
- EC 50, 174, 176
- ECG, 33–34, 40, 54, 143, 307, 309, 310, 311, 312, 313, 314, 411–412, 418
 electrode configurations, 312–313
 interpretation, 313–315
 leads, 311
- ED 50, 174, 176, 206
- effector, 3, 75, 93, 168
- electric charge, 318, 406, 409
- electric shock, 413
 microshock, 415
- electrical equipment, 412–413, 418
- electrical interference, 309, 411
- electrocardiogram, 33, *see* ECG.
- electrode systems, 422
- Embsden–Meyerhof pathway, 109
- enantiopure preparation, 181
- endothelial cells, 62, 64–65
- end-plate potential, 85, 213
 miniature, 85, 213
- entonox, 212, 332, 333–334
- entrainment ratio, 326
- eosinophils, 139
- ephedrine, 81
- epileptic patients, 188, 244
- erythromycin, 258, 283
- esmolol, 250
- ester hydrolysis, 215, 237
- esters, 65, 154, 192, 226
- etomidate, 60, 121–122, 172, 192, 194, 398
- excitation–contraction coupling, 87, 119
- excretion, 101, 102, 123–124, 154, 160–161, 171–172, 252–253, 402
- exercise, 4, 28, 32, 40, 51–54, 115
 aerobic, 51
 anaerobic, 51
 static, 51
- expiratory reserve volume, 1–25, 73
- exponential functions, 156
- extra-cellular fluid, 4, 62, 91–92, 99
- extra-cellular water, 93
- fast atrial fibrillation, 256
- fast glycolytic fibres, 89
- fast oxidative-glycolytic fibres, 88
- fast twitch muscle fibres, 51
- fats, 51, 108, 110–111, 117, 127–128, 130, 137, 275
 metabolism, 111
- fentanyl, 151, 162, 189, 194–195, 236
- fetal blood, 147
- fetal circulation, 146, 147–148
- fetus, 147–148
- fibrin degradation products (FDPs), 134
- fibrinolysis, 134–135
- Fick principle, 42, 61, 400, 402
- filtration fraction, 105
- first-pass metabolism, 151, 155, 272
- Fleisch pneumotachographs, 331
- flow
 laminar, 323, 325, 330–331, 408
 turbulent, 323–325, 427
- flowmeters
 ejector, 351
 rotameters, 326–331
- fluid compartments, 91–92
- Fowler's technique, 13
- fuel cells, 353, 357, 358–359
- functional residual capacity (FRC), 1, 24, 143
- fungi, 280, 284
- GABAA receptors, 167, 245
- GABA receptors, 241, 243, 245, 247
- gain (amplification), 309
- gamma-amino butyric acid, 167, 210
- gas chromatography, 353, 355–356, 367
- gas cylinders, 332
 critical temperature, 333
 filling ratio, 209, 334
 materials, 335
 nitrous oxide, 334
 pin-index system, 334
 pressures, 386, 389
 pseudocritical temperature, 333
- gas cylinders, testing, 335
- gas flow, measurement, 328–329
- gastric mucosa, 100, 154, 267–268
- Gay–Lussac's law, 320
- gelatins, 94, 96

	Index	433
glomerular filtration rate, 95, 103–105	context-sensitive, 161–162, 189	human albumin solutions, 96
glucocorticoids, 109, 115, 118, 121–122, 273	halothane, 23, 199, 203–204, 207, 344–345, 348, 350, 358	humidifiers cascade, 382 hot water bath, 382 nebulisers, 152, 262, 326, 382
gluconeogenesis, 109, 125–126, 128, 136–137, 261, 262, 275, 276	halothane hepatitis, 203	humidity, 328, 371, 379 absolute, 379, 381 measurement, 379–381 relative, 379–381, 416
glucose, 51–52, 88, 96, 104–105, 108–109, 126–127, 231, 274–277	Hashimoto’s thyroiditis, 118	humoral immunity, 140
brain, 57	Hasselbalch equation, 98	Humphrey ADE circuit, 340
CSF concentration, 63	heart, 18–20, 37–43, 47, 53, 254–255, 307, 311–312, 415	hydralazine, 251, 253
glomerular filtration rate, 104–105	arrhythmias, 219, 258, 271	hydrogen ions, 4, 41, 53, 97, 99, 101–102, 266, 364–366
metabolism, 89, 95	cardiac arrest, 42, 81, 219, 231, 232, 260, 261, 370	hydroxyethyl starch, 96
sources, 15, 108 <i>see also</i> glycogenolysis; glycolosis.	cardiac cycle, 33–34, 41, 395	hypercarbia, 23–24, 237
glucose-6-phosphate, 51–52, 108–109, 126	cardiac ischaemia, 194, 250, 262	hyperkalaemia, 84, 219–220, 253, 258, 263
glucose tolerance tests, 274	cardiac muscle, 37, 45, 86, 111, 254, 259, 327, 422	hypertension, 66, 73, 128, 129, 249–250, 274, 397, 398
glucuronic acid, 246	failure, 50, 189, 221, 250, 252–253	acute, 66
glucuronide conjugates, 186, 240	venous drainage, 18, 39–40, 55–56, 130, 397 <i>see also</i> cardiac output	hypertensive emergencies, 194, 251, 253
glycerol, 109, 111, 126, 185, 187	heart	hyperthyroidism, 28, 50, 118, 250, 259
glyceryl trinitrate, 41, 249–250, 251	valvular disease, 50	hypotension, 73, 75, 145–146, 208, 249–251, 267, 269, 272
glycogen, 108–109, 128, 129	heat, 374	hypothalamus, 4, 93, 107, 111–113, 114, 115, 117, 123
glycogenolysis, 108–109, 126, 251, 261–262	heat loss, 53, 113, 371–373, 379	hypothermia, 26, 28, 31, 215, 217, 364, 370, 372–373
glycolysis, 15, 28, 51–52, 109–110, 126	heavy marcan, 231	perioperative, 373
glycopyrronium, 256	helium, 205, 325, 332, 355, 422	hypothyroidism, 118–119, 207, 259, 372
gonadotrophin releasing hormone, 114	hemicholinium, 214	hypoxia, 19, 24, 28–29, 31–32, 59–60, 232, 235, 237
gonadotrophins, 114–116	Henderson–Hasselbalch equation, 98, 99, 227	hypoxic pulmonary vasoconstriction, 19, 22–23, 30–31
G-protein coupled receptors, 79, 112, 168, 221, 234, 260	Henry’s law, 321–322	hysteresis, 7
G-proteins, 79–80, 112, 167–169, 172, 221, 234, 260, 268	heparin, 104, 134, 239, 285–289, 366, 391	
growth hormone, 112, 114–115, 144	heparin-induced thrombocytopenia (HIT), 286–287	
guanylate diphosphate, 168	hepatic extraction ratio, 151	
guanylate triphosphate, 168	hepatic lobule, 131–132	
gynaecomastia, 258, 267	Hering–Breuer reflex, 4	
	hexose monophosphate shunt, 109, 111	
haemoglobin, 25–27, 29, 100, 135–136, 144, 252, 274, 360	high positive pressure ventilation, 24	
haemostasis, 128, 133, 421	high saturated vapour pressure, 197, 344, 346	
half-life, 158	histamine, 131, 139, 265–267, 270, 272	
	Hoffmann degradation, 154	
	Hoffmann elimination, 215	
	hormones, 111–114, 117, 119, 120–121, 124–126, 136, 147, 267	
		ibuprofen, 239
		ICP monitoring, 396
		immune response acquired, 141–142 innate, 138, 142 primary, 141 secondary, 141
		immunity acquired, 138–142 adaptive, 140 cellular, 138, 140

- immunity (cont.)
 humoral, 140
 innate, 138
immunoglobulin, 141
incretin pathway, 276, 277
inductance, 410, 418, 426
inferior infarcts, Isolated, 40
inflammation, 66, 123, 139,
 142, 230, 238, 282
inflammatory response, 128,
 139
infrared analysers, 353–354
inhalational agents, 65,
 197–207, 348, 367
innate immune response, 138,
 142
inotropes, 81, 259–262
inspiratory reserve volume, 1
insulin, 109, 111–112, 117,
 126, 128, 273, 275,
 277
insulin-like growth factor,
 115
interstitial fluid, 91, 106
Intra-cellular fluid, 91
intrapleural pressure, normal, 4
intravascular compartment,
 91, 94–95
intravascular fluid, 91
intubation, endotracheal, 324,
 378, 381
isobolograms, 173
isoflurane, 179–180, 199,
 201–203, 207,
 344–346, 348,
 349–350, 388
Isolation transformers, 412
isomers, 178–181, 190
 cis-cis, 180
 cis-trans, 180
 functional, 180
 geometric, 180
 stereoisomers, 179–180, 216
 structural, 179, 201
 trans-cis, 180
 trans-trans, 180
isoprenaline, 81, 260
isotonic exercise, 51
isovolumetric contraction,
 33–34, 36, 37
jet entrainment, 326
jugular bulb catheterisation,
 61
juxta-glomerular apparatus,
 124
kallikrein, 139
ketamine, 167, 175, 177,
 190–191, 194, 210, 398
ketorolac, 239
Kety–Schmidt technique, 61
kinetics
 first-order, 164–165, 242
 Michaelis-Menten, 164–165
 zero-order, 164, 188, 242
knee jerk, 75, 89
Korotkoff sounds, 389
Krebs cycle, 109, 136
labetalol, 250–251, 253
lactate, 51–52, 61, 64, 66, 109,
 126
lactic acid, 41, 52, 54, 89
Lambert's law, 360–361
laminar flow, 323, 325,
 330–331, 408
lamotrigine, 241, 243
lansoprazole, 267
Laplace's law, 7–8
lasers, 416, 420–422
lateral cortico-spinal tract, 72
laudanose, 215
left coronary artery, 39
left ventricular pressure curve,
 35
leucocytes, 138–139
lidocaine, 194, 207, 226–231,
 232, 254, 258, 260
lipid solubility, 150, 152–153,
 157, 200, 206, 228–230
lipolysis, 80, 115, 126, 128,
 261, 262
Lipoxygenase, 238
liquids, 319
lithium, 118, 216
liver, 111, 126, 129–130, 131,
 132, 137, 151,
 271–272, 275–276
 bile production, 130, 132
 blood flow, 130–131, 132,
 151, 198
 creatinine synthesis, 137
 cytochrome P450 system,
 154
 deamination, 137
 fat metabolism, 111
 first-pass metabolism, 171
 functional unit, 131
 functions, 129
 gluconeogenesis, 109, 126
 glycogen storage, 126, 127
 glycolysis, 51
 hepatic lobule, 132
 immune function, 130
 ketogenesis, 126
 protein synthesis, 129, 137
 liver blood flow, 130, 131
 liver first-pass metabolism,
 151
 loading dose, 155, 159, 163,
 257, 258
 local anaesthetics, 65, 148,
 151, 153, 216–217,
 226–232, 260, 261
 toxicity, 231–232, 279
 log-dose response curve,
 176–177
lungs
 compliance, 5–7
 volumes, 2, 6, 10–11, 22,
 23–24, 320
 expiratory reserve, 1–25,
 73
 functional residual
 capacity (FRC), 1, 24,
 143
 inspiratory reserve, 1
 low levels, 11, 24
 tidal, 1, 14–15, 54, 202,
 204, 235, 237, 329
 vital capacity, 1, 5, 73
 see also alveoli.
lymphocytes, 130, 139, 140
MAC, 60, *see* minimum
 alveolar concentration.
macrolides, 281, 283
macrophages, 130, 138–140
Magill circuit, 338–339
Magill circuit, 338, *see*
 Mapleson A breathing
 system.
major haemorrhage, 263, 300
major obstetric haemorrhage,
 144
malignant hyperpyrexia, 183,
 219, 370
malignant hyperthermia, 162,
 183, 195, 198, 202, 204,
 219–220
manometers, 386–389
Mapleson classification,
 338–341, 348
 type A breathing system,
 338, 341
 type B breathing system,
 340
Marsh model, 190

	Index	435
mass spectrometry, 353, 355, 357, 367, 379–380	myogenic control, 102	latent heat of vaporisation, 334
maternal–fetal circulation, 146	myopathy, 119, 259	manufacture, 209
medulla, 3–4, 47–48, 55, 63, 72, 106–107, 120, 269–270	critical illness, 216	mass spectrometry, 355
meglitinides, 276	natural frequency, 393, 394	maximum allowable concentration, 207, 350, 398
MET, 50, <i>see</i> metabolic equivalent	nausea, 30, 182, 222, 257, 258, 268, 301	mechanism of action, 210
metabolic equivalent, 50–51	nebulisers, 152, 262, 326, 382	paramagnetic oxygen analysis, 360
metabolic rate, basal, 50–51, 108, 127, 262	neonates, 2, 58, 67, 153, 324, 325, 375, 381	physical properties, 209
metaraminol, 81	neostigmine, 166, 172, 223–224	piezoelectric analysis, 356
metformin, 276–277	Nernst equation, 68–69	second gas effect, 211
methionine synthetase, 211–212	nerve, glossopharyngeal, 4, 47–48	storage, 209, 332–333
metoclopramide, 171, 244, 258, 268, 270–273	neuraxial anaesthesia, 146	toxicity, 211
metronidazole, 242, 281, 283	neuraxial block, 287, 289	N-methyl-D-aspartate (NMDA), 210
MH, 162, <i>see</i> malignant hyperthermia.	central, 289	non-depolarising neuromuscular blockers, 215, 216, 218
midazolam, 173, 180, 246–247	neuroleptic malignant syndrome, 272	non-normal distribution, 292
mineralocorticoids, 121, 124	neuromuscular blockade, 195, 214, 216–218, 220, 222, 224–225, 311, 315–318	non-steroidal anti-inflammatory drugs, 237–239, 268, 285, 287, 289
minimum alveolar concentration (MAC), 60, 197–201, 204, 205–207, 209–210, 398	non-depolarising, 155, 173, 318	noradrenaline, 65, 79, 81, 125, 154, 255, 259–262
mivacurium, 180, 215	neuromuscular junction, 82–84, 171, 213–215, 217–218, 222–225, 315, 316	normal distribution, 11, 292
Monge's disease, 31	neutrophils, 139, 140	normal glomerular filtration rate, 103
monocytes, 139	nifedipine, 23, 31, 251, 253	novel oral anticoagulants (NOACs), 285
monopolar, 422	nitric oxide, 23, 90, 168, 188, 209, 355, 359	NSAIDs, 237, <i>see</i> non-steroidal anti-inflammatory drugs.
Monro–Kellie doctrine, 57, 395, 399	nitroimidazoles, 283	
morphine, 129, 167, 182, 210, 234–237	nitrous oxide	
motor neurone excitation, 87	advantages, 209	Ohm's law, 408, 411, 413
motor neurones, 77, 82, 88–89, 90, 213–214	applicatytions, 208	oil:gas partition coefficient, 197–198, 200–201, 206, 207
mountain sickness, acute, 30–31	blood:oxygen partition coefficient, 199	omeprazole, 172, 267
movement, voluntary, 86, 89	capnography, 367	one-compartment model, 156, 157–159
MRSA, 282	cerebral blood flow and, 60	one-lung ventilation, 19
multiple sclerosis (MS), 64, 66	co-administration, 200, 206	opioid receptors, 190, 210, 234–235, 236, 270, 271
muscle cell, Smooth, 90	concentration effect, 211	opioids, 60, 119, 194, 207, 234, 235–237
muscle contraction, 46, 76, 78, 84, 86–88, 90, 213, 263	critical temperature, 333	effects
facial, 316	diffusion hypoxia, 211	cardiovascular, 235
skeletal, 86–87	disadvantages, 210	gastrointestinal, 236
muscle metabolism, 86, 88	discovery, 208	respiratory, 235
muscle spindles, 76–77, 86, 89–90	entonox, 212	oscillating systems
myalgia, 195, 219	environmental effects, 205	natural frequency, 393
myocardial infarction, 32, 42, 137, 313, 327	filling ratio, 209	resonance and damping, 393–395
myocardium, 37–38, 41–42, 44, 129, 230, 415, 417, 420	high concentrations of, 200, 211	
	hypoxic pulmonary vasoconstriction and, 23	

- osmolality, 63, 92, 106–107
 osmolarity, 92, 105–107
 oxygen analysers,
 paramagnetic, 359–360
 oxygen cascade, 17, 25, 30
 oxygen concentration
 alveolar, 21
 capillary, 21
 inspired, 15, 19, 326, 422
 mixed venous, 21
 oxygen concentrators, 337
 oxygen consumption,
 myocardial, 40
 oxygen content, 20, 402
 capillary, 20
 venous, 20, 402
 oxygen, partial pressure of, 16,
 17–18, 25, 27, 30,
 52–53, 359
 oxygen saturation, 27, 30, 61,
 130, 132, 147–148,
 220, 361–363
 arterial, 360–362
 oxygen tension, alveolar,
 15–16
 oxyhaemoglobin dissociation
 curve, 27, 373
- P50, 27–29
 pacemaker, 46, 424
 pacemaker action potential,
 44, 46
 pacemaker cells, 42–43, 44,
 46–47, 86, 230, 254
 pantoprazole, 267
 para-aminohippuric acid, 105
 paracetamol, 239–240
 parasympathetic nervous
 system, 41, 78–79, 82,
 257, 262
 parietal cells, 264–267
 Parkinson's disease, 65, 273
 partial agonists, 174–175, 177,
 190
 partial pressure, alveolar, 32,
 199–200
 Pathogen-Associated
 Molecular Patterns
 (PAMPs), 139, 406
 penicillins, 281–283
 perfect gas laws, 319–320
 first, 319
 second, 320
 third, 320
 peripheral vasoconstriction,
 73, 113, 362, 391
- pH, 96–102, 153–154,
 186–187, 227–230,
 246–247, 265–267,
 363–366
 cerebrospinal fluid, 4
 pharmaceutical
 incompatibility, 171
 pharmacodynamics, 165, 188,
 191, 202, 242, 275
 pharmacogenetics, 182, 183
 pharmacokinetic models
 one-compartment, 156,
 157–159
 three-compartment,
 160–161, 162
 two-compartment, 160
 pharmacokinetics, 129, 149,
 181, 184–186, 187,
 191, 197, 201
 phenobarbitone, 151, 187
 phentolamine, 251
 phenylalanine, 66, 136
 phenylephrine, 81, 146, 148
 phenytoin, 151, 153, 169–172,
 241–244, 254,
 258–259, 398–399
 PiCCO systems, 405
 piezoelectric effect, 318, 356,
 426
 Piped medical gases and
 vacuum (PMGV), 335
 pipelined gases, 332, 335–337
 piperidines, 271
 pituitary, 67, 93, 95, 112–115,
 117, 118, 123–124,
 128–129
 anterior, 67, 112–115, 117,
 123–124, 128, 145
 posterior, 67, 93, 95,
 113–114, 128
 pKa, 99–100, 150, 185,
 186–187, 190,
 227–230, 236
 placenta, 85, 144, 146–148,
 153
 placenta accreta, 148
 placental barrier, 153
 plasma calcium, 119–120
 plasma concentration,
 149–150, 156,
 157–159, 161–162,
 164, 208, 215, 248
 plenum vaporisers, 343
 pneumotachographs, Fleisch,
 331
 pneumotachography, 330–331
- hot-wire, 331
 Pitot tube, 331
 polycythaemia, 30, 31–32, 363
 porphyria, 189, 192
 posterior/dorsal columns, 72
 potassium, 66, 68–69, 106,
 107, 124, 169–170,
 217, 220
 potential difference, 68, 69,
 304, 357–358,
 407–411, 413,
 417–418, 419
 potentiation, 173, 287
 power of a study, 296
 Poynting effect, 212, 334
 pre-eclampsia, 143, 194, 250,
 253
 pregnancy, 28–29, 143–145,
 217, 221, 243, 253,
 273
 airways and breathing,
 143
 circulation changes, 143
 early, 143–145
 endocrine changes, 144
 gastric changes, 144
 general anaesthesia, 145
 haematological changes,
 144
 maternal–fetal circulation,
 146
 neuraxial anaesthesia,
 145–146
 pre-motor area, 89
 pressure
 absolute, 320, 386
 ambient, 32, 207, 321–322
 aortic, 21, 34–35
 barometric, 30
 cerebral perfusion, 56, 58,
 62, 188, 396
 diastolic, 53, 390, 394–395
 gauge, 209, 320, 386
 intrapleural, 4–6, 10–11
 intra-thoracic, 48–49, 50, 53
 pulmonary artery, 12,
 21–22, 24–25, 34
 units of, 304, 306, 383
 pressure–volume curves, 2–3,
 5, 6–7, 36, 57
 prochlorperazine, 244, 271,
 273
 pro-drugs, 153–154
 prokinetic drugs, 268
 prolactin releasing hormone,
 114

- propofol, 162, 185, 187, 189,
 193–194, 373
 absorption, 186
 cardiac effects, 188
 cerebral blood flow and, 58,
 60
 distribution, 186
 dose, 187
 epilepsy, 244
 formulation, 185
 gastrointestinal effects,
 188
 intracranial pressure and, 398
 mechanism of action, 187,
 188
 metabolism, 186
 neonates, 153
 pain on injection, 189
 pharmacokinetics, 187–189
 physical properties, 187
 remifentanyl and, 164
 renal/hepatic effects, 188
 respiratory effects, 188
 seizure management, 232,
 243
 structure, 185
 summation, 173
 total intravenous
 anaesthesia, 189–190
 prostaglandins, 41, 139,
 237–238, 267–268
 protamine, 287
 protein binding, 152–153, 155,
 228–230, 232
 protein metabolism, 128, 275
 proteins
 basic structure, 135–136
 catabolism, 137
 in diet, 136–137
 quaternary, 136, 137
see also amino acids.
 pseudocritical temperature,
 212, 333–334
 pulmonary hypertension,
 22–24, 31, 314
 pulmonary vascular
 resistances (PVR),
 22–25, 147
 pulse oximeter, 360–363
 purines, 136–137
 Purkinje fibres, 42–43
p value, 295–296, 298–299
 qualitative data, 291, 297
 quantitative data, 291–292
 quinolones, 29, 281, 283
 racemic mixtures, 181, 190,
 229
 Raman spectrometry, 353, 356
 rapid sequence induction, 145,
 193–195, 218
 recombinant Tissue
 Plasminogen
 Activators (rTPAs),
 135
 reflex arc, 75, 77
 basic, 75
 monosynaptic, 75, 89
 refractory period
 absolute, 45–46, 69–70
 relative, 45–46, 70
 refractory period of action,
 254
 remifentanyl, 153, 162, 164,
 189, 194, 235, 237
 renal blood flow, 53, 102, 105,
 238, 252, 262
 residual current devices, 412
 resistance, 411
 resonance, 393–395
 resonance and damping, 395
 respiratory centre, 3–4, 54, 63,
 235
 respiratory shunt, 19–20
 resting membrane potential,
 44, 46, 68
 Reynold's number, 325
 rifampicin, 151, 172, 281, 283
 right coronary artery, 39, 40
 rocuronium, 194–195, 215,
 216, 218, 224–225, 244
 ropivacaine, 226, 228–231
 rotameters, 326–331
 RSI, 145, *see* rapid sequence
 induction.
 sacral nerves, 78
 salbutamol, 80, 81, 260
 salmeterol, 31
 sarcomere, 86–87
 scavenging, 339, 350, 351–352
 active, 350–351
 passive, 350–351, 352
 second gas effect, 200, 210,
 211
 Severinghaus electrode, 363,
 365–366
 sevoflurane, 60, 199, 201–202,
 206, 207, 322–323,
 342, 348–349
 shunt equation, 19–20
 sickle cell disease, 26
 Siggaard-Andersen
 nomogram, 101, 367
 sildenafil, 23, 31
 sinuses of valsalva, 40, 48, 50
 sinus tachycardia, 30
 skeletal muscle, 40, 75–78, 84,
 86, 88, 108, 111,
 307–308
 muscle fibres in, 51
 skewed distribution, 293–294
 slow twitch muscle fibres, 51
 SMMACKK (mnemonic),
 303
 soda lime, 197, 204, 338, 341,
 346–349
 sodium-glucose transporter 2
 (SGLT-2) inhibitors,
 276
 somatomedins, 115
 somatotrophs, 114
 spinal cord, 63, 70–71, 73–74,
 75, 77–78, 82, 89–90,
 245–246
 spinocerebellar tracts, 72
 spinotectal tract, 72
 spirochaetes, 280–281
 spirometry, 1, 6, 328–329, 402
 splanchnic vasoconstriction,
 188, 261, 262
 standard deviation, 292,
 294–295
 standard error of the mean,
 294–295
 standard temperature and
 pressure, 305, 321, 322
 staphylococci, 280, 281, 283
 starches, 94, 96
 starvation, 109, 111, 125–127
 status epilepticus, 242, 243
 steroid hormone synthesis,
 121
 steroids, 8, 65, 151–152, 272
 strap muscles, 116
 streptokinase, 42, 135, 289
 stress response, 115, 125,
 127–129, 131
 anaesthesia and, 129
 ebb phase, 127
 stroke volume (SV), 30, 34, 37,
 53, 143, 400, 401, 405
 Student *t* test, 298–299
 sugammadex, 195, 218,
 224–225
 sumatriptan, 31
 summation, 86, 173, 213, 307
 surfactant, 7–8

- suxamethonium, 84, 171, 195,
 215, 217–219, 224,
 318, 398
 apnoea, 183
 breakdown, 85
 contraindications, 195
 denervation
 hypersensitivity, 84
 depolarising neuromuscular
 blockade, 214–215
 malignant hyperthermia,
 183
 metabolism, 195
 pregnancy, 145
 rapid sequence induction,
 195
 suxamethonium, 84, 171, 182,
 183, 195, 214–215,
 217–219, 224
 sympathomimetic drugs,
 80–81
 sympathomimetics, 80–81
 synaptic cleft, 82–85, 170, 172,
 213
 synergism, 173, 194
 systolic blood pressure, 250,
 262, 291, 384,
 389–390, 394–395
 tachycardia, 41, 47, 48–50,
 128, 129, 188, 208, 251
 target-controlled infusions
 (TCI), 162–164
 temperature, 374
 core body, 372, 378
 measurement, 375
 units, 374
 temperature compensation,
 344
 temperature measurement,
 infrared, 378
 tetracyclines, 150, 216, 281, 283
 theatre ventilation systems,
 349–351, 352
 thermistors, 366, 375–377,
 381, 403, 405, 408
 thermocouples, 375–376, 377
 thermodilution techniques, 42,
 402, 405
 thermometers, 375, 378,
 379–380
 alcohol, 375
 chemical, 375
 dial, 375–376
 liquid expansion, 375
 mercury, 375
 resistance, 375–376
 tympanic membrane, 375,
 378
 thermoreceptors, 77, 113
 thiazolidinediones, 276–277
 thiopental, 145, 185, 193, 232
 thiopentone, 58, 60, 153, 164,
 171, 184–189, 193,
 243–244
 thioridazine, 271
 thrombin, 133–134, 286, 288
 thrombin burst, 133
 thyroid, 117
 thyroid gland
 anatomy, 116
 histological composition,
 116–117
 thyroid hormones, 115,
 117–118
 thyroid releasing hormone,
 114–115
 thyrotropin releasing
 hormone (TRH), 117
 thyroxine, 66, 112, 117
 tidal volume, 1, 14–15, 54, 202,
 204, 235, 237, 329
 time constant, 158–160, 369
 tissue factor pathway inhibitor
 (TFPI), 134
 tissue oxygenation, 28, 30
 T lymphocytes, 140, 141
 Torricelli barometer, 387
 total body water, 91–93, 95
 trachea, 116, 196, 214, 381
 intubation, 118, 193, 243
 tranexamic acid, 134–135,
 300–301
 Tranexamic acid, 134–135,
 300–301
 transamination, 137
 transcellular fluid, 91–92
 transcranial Doppler
 ultrasonography, 61,
 427
 transdermal absorption, 151
 trauma, 63, 64, 127–128, 219,
 301, 396, 399
 traumatic brain injury, 194,
 301, 396, 399
 tricarboxylic acid cycle, 110,
 136
 trichloroethylene, 348
t test, 298–299
 tumour necrosis factor (TNF),
 139
 Tuohy needle, 74
 tympanic membrane, 378
 type 1 error, 296
 type 2 error, 296
 ultrasound, 353, 400, 425–427
 umbilical vein, 146
 urea, 104–106, 129, 137, 252,
 253, 278
 urine, 94, 104–105, 106, 154,
 182, 215, 237, 276–277
 urine, concentrated, 106
 urine osmolality, 93
 urokinase, 135, 289
 vacuum-insulated evaporator,
 335–336
 vagus nerve, 4, 43, 47–48,
 266
 Valsalva manoeuvre, 47, 48,
 49–50
 vaporisers, 32, 201, 322–323,
 342, 344, 345, 346
 desflurane, 32, 343, 346
 plenum, 342–343, 345–346
 use at high altitude, 346
 vaporising chamber, 342–345
 vasa recta, 106
 vascular resistance,
 pulmonary, 22, 23–24,
 146–147
 vascular smooth muscle, 59,
 80, 90, 170
 vasoconstriction, 22, 47,
 48–49, 131, 133, 166,
 169, 228
 vasoconstrictors, 102, 122,
 231–232
 vasomotor centres, 47–48
 Vaughan–Williams
 classification, 253–255
 class I, 254
 class Ia, 254
 class Ib, 254
 class Ic, 254
 vecuronium, 215, 216,
 224–225, 244
 ventilation, 3–4, 9–12, 54,
 73–74, 143, 204, 211,
 397
 dead-space, 12
 ventricular fibrillation (VF),
 230, 232, 257, 373,
 413–415, 418, 422
 ventricular pressure, 33–36
 Venturi principle, 326
 verapamil, 251, 254–257

		Index	439
vital capacity, 1, 73	von Recklinghausen	Wheatstone bridge, 376, 391,	
vitamin B12, 211	oscillotonometer,	408	
vitamin D, 119–120	389–390	Williams classification,	
vitamin K, 134, 243, 287–289	von Willebrand factor, 96,	254–255	
volatile agents, 200, 205,	133	Willis circle, 55–56	
207–208, 210, 211,	warfarin, 152, 239, 242, 259,	work of breathing, 2–3, 205,	
341–346, 353–354,	267, 285, 287–288, 289	325, 337	
356	water, intracellular, 91, 93	xenon, 9, 199, 204–205, 207	
volume of distribution, 155,	water reabsorption, 93,		
157–159, 186, 188, 191	106–107, 123	zona glomerulosa, 120–121,	
vomiting, 191–192, 236, 237,	Waters circuit, 340, 348	124	
258, 268–273, 298,	West zones, 11	zona reticularis, 120–121	
396, 398			